Manas AI

Manas AI focuses on revolutionizing drug discovery, particularly in oncology, by leveraging AI and computational power to develop treatments for aggressive cancers like triple negative breast cancer, prostate cancer, and lymphoma. The company operates in the pharmaceutical and biotechnology market, targeting both cancer and rare diseases. Utilizing proprietary AI models, generative computational chemistry, and advanced biology, Manas AI aims to significantly reduce drug development timelines and costs. The business model involves creating bespoke chemical libraries and employing AI filters to identify high-potential therapeutic candidates with unprecedented speed and accuracy. Manas AI's partnership with Microsoft enhances its capabilities by integrating world-class AI infrastructure, enabling molecular docking speeds 100 times faster than traditional systems. The company serves pharmaceutical companies and research institutions seeking efficient and cost-effective drug development solutions. Keywords: oncology, AI, drug discovery, cancer treatment, computational chemistry, molecular docking, pharmaceutical, biotechnology, therapeutic candidates, Microsoft partnership.